11/3/2026

speaker
Conference Call Operator
Operator

and welcome to today's ADAPT Health third quarter 2026 earnings release. Today's speakers will be Suzanne Foster, Chief Executive Officer of ADAPT Health, and Harris Curry, Chief Financial Officer of ADAPT Health. Before we begin, I'd like to remind everyone that statements including in this conference call and in the press release issued today may constitute forward-looking statements within the meaning of private securities litigation reform act. These statements include, but are not limited to, comments regarding financial results for 2026 and beyond. Actual results could differ materially from those projected in forward-looking statements because of the number of risk factors and uncertainties which are discussed at length in the company's annual and quarterly SEC filings. Adapt Health Corp. has no obligation to update the information provided on this call to reflect such subsequent events. Additionally, on this morning's call, the company will reference certain financial measures, such as EBITDA, adjusted EBITDA, adjusted EBITDA margin, and free cash flow, all of which are non-GAAP financial measures. You can find more information about these non-GAAP measures in the presentation materials accompanying today's call, which are posted on the company's website. This morning's call is being recorded, and a replay of the call will be available later today. I'm now pleased to introduce the Chief Executive Officer of Adapt Health, Suzanne Foster.

speaker
Suzanne Foster
Chief Executive Officer, ADAPT Health

Good morning, everyone, and thank you for joining us today. First order of business is to welcome Harris Curry, who joins Adapt Health as our Chief Financial Officer in September. Harris will take you through our financial results in our book after my remarks. The third quarter was a step in the right direction. We delivered strong organic growth exceeded our guidance for revenue and adjusted EBITDA, and met our pre-cash flow target, driven in large part by meaningful improvement in the performance of our largest capitated contracts and by a base business that continues to produce consistent performance. This morning, I'll overview our third quarter results, update you on the two issues that weighed on our outlook last quarter, The Capitated Contract and an Unexpected Price Increase from a Large Manufacturer, and then give you a brief update on the pending sale of our diabetes health business and our Medline's Field Action Announcement about expense. Starting with our results, as a reminder, all figures are provided on a continuing operations basis, including prior period comparisons, except for capital expenditures and free cash flow. which will include diabetes health until the sale closes. Third quarter net revenue was $745.6 million, up 10.9% versus the prior year quarter and up 12.8% on an organic basis. Adjusted EBITDA was $141.9 million, $11.2 million above the midpoint of our implied third quarter guidance range, and Free Cash Flow was $51.1 million, slightly ahead of our guidance. Terrence will take you through the details in a moment. Behind these results, the biggest driver was the improvement in our largest capitated contract and specifically the West Coast operations associated with that contract. We have been working to stabilize the operation and align costs to serve with our original assumptions. and that work is now beginning to pay off. The contract made a positive contribution to adjusted EBITDA in the quarter, a swing from a loss in the second quarter and better than break even we assumed for the second half when we reset guidance in August. Two dynamics drove the improvement. First, utilization, while still well above our original expectations, has come down from the peak of the early months. particularly in sleep resupply as the backlog of pen prep demand cleared. Capital spending also declined sequentially as we completed the one-time purchase of vehicles and initial buildup of patient equipment. Second, we tightened the labor model. Headcount dedicated to the contract, including temporary staff, couriers, and contract workers, is down more than 12%. Since the end of the second quarter. As a result, we have lowered our costs, even with utilization still elevated, and while exceeding our service level requirements and commitments. We are certainly encouraged by the trajectory of the contract's profitability. September's run rate margin contribution was stronger than July's. and the progress we are making gives us confidence we will achieve a 20% margin on the contract by the fourth quarter of next year. We also continue to work with our partner on the economics of the contract and are making progress with those discussions. The data supports our premise that utilization was running above our expectations on which the contract was priced. We have been provided assurances that pricing adjustments are coming. While we do not yet know the final impact of our negotiations, we are holding on any unilateral movements under the agreement while we continue to negotiate in good faith as partners. Although we expect the agreement to be modified this quarter, we have not assumed a change to the terms in the revised outlook we are providing today. As I mentioned last quarter, there is also an opportunity to use our newly established reprints to serve patients beyond the capitated membership. The moratorium on enrollment of new suppliers in Medicare that directly affected us was lifted in August, and we are submitting our applications for new PTANs, which are the Medicare billing numbers that allow us to operate more broadly in California. This will ultimately allow us to compete for fee-for-service business in that market. As a reminder, that opportunity is not included in our contract margin target of at least 20%. Next, the manufacturer price increase. As a reminder, we were notified on June 30 that a manufacturer was terminating their contract and imposing an immediate price increase. which we estimated would reduce second half adjusted EBITDA by approximately $30 million. Since then, we have reached an agreement on a rebate structure that allows us to recover a portion of the lost economics. We realized the benefit of $8 million in the third quarter as a result of purchases made during the quarter. We will carefully rate further opportunities to capture discounts within this arrangement as well as across all of our vendors against our business needs and cash flow management. So we have an arrangement in place for the 2026 contract year and we are now back to our normal annual negotiation cycle with the manufacturer. Turning to the portfolio, a brief update. The NHSR waiting period has expired for the sale of our diabetes health business to Cardinal Health. Transition activities are progressing as planned and we expect to close early in 2027, subject to customary closing conditions. As a reminder, following the move of Diabetes Health to discontinued operations, our continuing operations results carry about $60 million of corporate overhead that was previously allocated to that business. Of the $60 million, About half has been specifically associated with diabetes health activity and is expected to dissipate beginning on day one through 12 months after the close of the transaction. The remaining $30 million of overhead is true stranded cost that we expect to absorb through growth and expense discipline over the next few years. With the portfolio work now largely behind us, We are a focused sleep, respiratory, and wellness-at-home business where growth and margins are more attractive. The clinical value we add is greater, and our resupply operations keep us in a continuing relationship with patients. Now a word on Medline. You may have seen that Medline has announced it is removing its brand of beds from the market following earlier safety notices on certain home care beds. We are following Medline's instructions. We are communicating directly with affected patients and caregivers and we are working to repair or replace affected beds on a reasonable timeline. Medline beds are a meaningful part of our bed suite and the replacement will take place over multiple quarters. We expect Medline to stand behind its products and we are working with them to address the full cost of replacement. We will update you as that work progresses. We saw continued evidence this quarter that the underlying business is improving and stable. Our enterprise sales strategy is gaining traction as we signed preferred provider agreements with four large health systems. And we modernized our capitated portfolio with two smaller agreements with regional health plans, one new and one expanded. Our strategy is focused on being the easiest and most reliable supplier for patients and physicians to work with. Thank you so much for joining us. of those resulting in a completed order. Importantly, leveraging this technology also helps us control our labor and office costs. Let me close with where we go from here. The business is stabilizing after the largest patient transition in the history of the industry, and the third quarter demonstrates that the actions we took in the first half are gaining traction. With the pending sale of our diabetes health business, we are on the verge of completing our multi-year effort to focus our portfolio. Our priorities are to augment the returns on our largest capitated contracts and to return to delivering predictable, consistent results. Our base business continues to grow organically, and I'm grateful to our teams who have put patients first through our demanding year and are heading into next year with momentum. With that, let me turn it over to our new CFO, Harris, to review the financials.

speaker
Harris Curry
Chief Financial Officer, ADAPT Health

Thank you, Suzanne, and good morning, everyone. I'm certainly pleased to be here, and I look forward to meeting many of you in the near future. I'll cover our third quarter results, the balance sheet, cash flow, and our updated outlook. As noted, all figures are provided on a continuing operations basis, including the prior period comparisons, except for capital expenditures and free cash flow, which includes diabetes health, until the sale closes. Third quarter net revenue of $745.6 million increased 10.9% versus the prior year quarter, with organic growth of 12.8%. We displayed year-to-date growth in revenue over the prior year of 9.7%. Our third quarter revenue was $15.6 million above the midpoint of our guidance, driven primarily by growth in referrals and resupply in our sleep health segment and a slower than anticipated reduction in revenue related to the decision to cease actively marketing certain products within our PCS business. On a reported basis, sleep health net revenue was $393.9 million, up 11%. Respiratory health net revenue was $190.8 million, up 7.8%. Wellness at home net revenue was $161 million, up 14.5%. Total capitated revenue was $110.3 million, about 15% of our continuing operations net revenue and more than three times that of the prior year. Our largest capitated contract contributed 10.7 percentage points of the 12.8% organic growth in the quarter. Base business organic growth contributed the remaining 2.1 percentage points of the 12.8% organic growth. Adjusted EBITDA was $141.9 million versus $146.1 million in the prior year quarter A margin of 19% versus 21.7% a year ago. On a year-to-date basis, adjusted EBITDA declined by 4.2%. The year-over-year and year-to-date declines reflect the ramp of our largest capitated contract, partially offset by labor and operating expense discipline. Total headcount. of 10,995 was down 337 from the end of June, the largest components of which were staffing reductions on the capitated contracts and overall discipline on labor. Adjusted EBITDA for the Corps was $11.2 million favorable against our guidance midpoint of $130.7 million. As Suzanne mentioned, The primary driver of this result was the largest capitated contract, which delivered a margin of approximately 10% in the quarter, up sequentially from a negative margin of 4% in the second quarter and was tracking at a run rate of approximately 14% as we exited the quarter. The balance of the adjusted EBITDA favorability to guidance came in stronger than anticipated revenue across our other revenue verticals, as well as enhanced cost discipline. On a GAAP basis, net loss attributable to ADAPT Health was $168.2 million, resulting primarily from $194.8 million non-cash, pre-tax, goodwill impairment charge, which was triggered by the recent decline in our equity market capitalization. Also, as a reminder, in the third quarter, we contributed our e-commerce business into a joint venture in exchange for a minority interest. As a result, we recognized 12 million pre-tax gain. Other items, the bill of impairment and the e-commerce contribution, are excluded from adjusted EBITDA. Turning to the balance sheet, we ended the quarter with net debt of $1.85 billion, down $48 million from June 30th and had a consolidated total leverage ratio of 3.05 times, essentially unchanged from the second quarter. Unrestricted cash was $80.7 million. And during the quarter, we redeemed our 6.25% senior notes due to 2028 with the proceeds of the $325 million delayed draw term loan, eliminating our highest cost tranche of debt and lowering our ongoing debt service obligation by approximately 17 basis points. We remain committed to our net leverage target of 2.5 times, and we intend to direct a significant portion of the diabetes health proceeds towards debt reduction. Free cash flow was $51.1 million for the quarter, in line with our guidance of approximately $50 million. Year-to-date free cash flow is $2.6 million, reflecting previous free cash flow deficits reported in earlier quarters. Capital expenditures were $105.5 million, or 14.2% of consolidated net revenue, compared to 18.1% year-to-date as the elevated spending to equip the capitated contract has subsided. Our capital allocation priorities remains unchanged. Reducing leverage, investing to accelerate organic growth, and pursuing disciplined, smaller tuck-in acquisitions. Turning to guidance. We are raising our full year net revenue range to $2.88 billion to $2.9 billion. An increase of about $20 million at the midpoint, mostly reflecting Our third quarter outperformance relative to our prior guidance. We are also adjusting our adjusted EBITDA range to 510 to 525 million, an increase of 12 million at the midpoint based on our third quarter results and the September run rate on the capitated contract margin. Our guidance also assumes modest sequential improvement on the capitated contract, No change to that contract's pricing structure and no further improvement in manufacturer pricing. At the bottom end of the range reflects consideration for any unanticipated short-term effects of the Medline field actions. For the fourth quarter, this implies net revenue of approximately $715 to $735 million and adjusted EBITDA of approximately $130 to $145 million. Now let me spend a moment on free cash flow. We're lowering our full year range to $55 to $80 million. As mentioned before, this range includes cash flow from Diabetes Health until the sale closes. The prior range communicated in August contains certain working capital assumptions, including the timing of vendor payments around year end, that has since been pulled over to prioritize early payment discounts over short-term cash accumulation. The range implies fourth quarter free cash flow of roughly $50 to $75 million or about $65 million at the midpoint of 30% sequentially. We believe the current free cash flow guidance represents baseline cash generation as we head into 2027 and we will continue to focus on prudent origin capital management. Our commitment is to run a business that can deliver sustainable, predictable and dependable growth with measurable consistency and to deliver reliably on our guidance. We built this entire outlook with that goal in mind. That brings us to the end of our prepared remarks. Operator, please open the call up for questions.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation